Publications by authors named "Tugce I Pasa"
Clin Cancer Res
August 2024
Article Synopsis
- Antibody-drug conjugates (ADCs) are effective targeted therapies for solid cancers, and this study focuses on the efficacy of EGFR-targeted ADCs for treating EGFR-amplified glioblastoma (GBM).
- The study compares two ADCs, Losatuxizumab vedotin (ABBV-221) and Depatuxizumab mafodotin (Depatux-M), for their effectiveness and toxicity using patient-derived models and nontumor-bearing mice through a delivery method called convection-enhanced delivery (CED).
- Results showed that CED significantly increased survival rates in GBM models, but ABBV-221 caused more neuronal toxicity compared to Depatux-M, raising concerns about the stability
